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 ABSTRACT                                                                                                                                            
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Background: It was recently reported that Duchene muscular dystrophy 
(DMD) patients and mdx mice have elevated levels of caveolin-3 expression 
in their skeletal muscles. However, it remains unknown whether this increased 
caveolin-3 levels contribute to the pathogenesis of DMD. Also mitochondrial 
DNA mutation in the tRNA methionin (tRNA Met) gene has been shown to be 
associated with muscle weakness, severe exercise intolerance, lactic acidosis 
and growth retardation. Since DMD is X-linked maternally inherited disease, 
mitochondrial mutation in tRNA (Met) gene can be suspected to be the cause 
for the inefficient splicing of dystrophin gene during its expression and can be 
implicated as the cause of dystrophin inactive protein. 
Aim of the Work: The aim of the present study is to investigate whether muta-
tions in caveolin gene leads to its increased expression and/or mutation in the 
tRNA (Met) gene can be associated with DMD pathogenesis. 
Patients and Methods: Expression of caveolin mRNA by RT-PCR and mu-
tations in caveolin gene and tRNA (Met) gene were measured in 28 patients 
presented with DMD symptoms using the single strand conformation polymor-
phism assay (SSCP). 
Results: Results gave further proof to decreased expression of inducible nitric 
oxide synthase (iNOS) mRNA, which leads to increased expression in caveolin 
3 mRNA in lymphocytes of DMD patients compared to controls. However us-
ing SSCP, there was no evidence for tRNA (Met) gene mutation among DMD 
patients and only one patient presented a mutation in the caveolin gene com-
pared to controls. 
Conclusion: There is an inverse relation between iNOS and Caveolin 3 in lym-
phocytes of DMD patients compared to controls. However, Caveolin 3 gene 
mutation is excluded as the main cause of increased caveolin gene expression. 
Also, there was no evidence for tRNA (Met) gene mutation among DMD pa-
tients.
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INTRODUCTION                                           
Duchene muscular dystrophy (DMD) 
is an X-linked (Xp21) recessive dis-
ease affecting 1 in 3,500 males, result-
ing in morbidity in childhood and early 
adulthood1. DMD is caused by a vari-
ety of mutations in the open reading 
frame of the dystrophin gene, resulting 
in a deficiency of the protein product 
and loss of function of the dystrophin-
glycoprotein complex (DGC)2. DGC 
plays a primary role in mechanical 
stabilization of the plasma membrane 
in striated muscles and provide hints 
for secondary functions in organizing 
molecules involved in cellular signal-
ing that allows the muscle to adapt to 
muscle activity by either atrophy or 
hypertrophy3,4. The DGC is composed 
of several protein components, which 
spans the muscle sarcolemma, linking 
the cortical cytoskeleton with the ex-
tracellular matrix5,6. Associated with 
the DGC complex is caveolin and nitric 
oxide synthase. Caveolin-3 is localized 
in the sarcolemma and co- fractionates 
with the original dystrophin complex 
(DC)7, while neuronal nitric oxide syn-
thase (nNOS) is normally localized to 
the membrane of muscle cells.8
Caveolin-3 protein is a product of the 
caveolin gene family and many signal-
ing molecules are localized to the cave-
olae and interact with caveolins9. The 
interaction of caveolins with signaling 
molecules has been implicated in the 
activation and in the inactivation of 
signal transduction events. One of the 
best characterized examples of this in-
teraction and its role in signal transduc-
tion is the binding of caveolins to in-
ducible nitric oxide synthase (iNOS)10. 
Interaction of caveolins with NOS is 
thought to hold the enzymes in an inac-
tive conformation and only release their 
inhibitory constraints through caveolin 
dissociation, allowing the signaling to 
take place11. Thus the decreased expres-
sion of nitric oxide synthases iNOS 
mRNA can lead to increase in caveolin 
mRNA. 
Nitric oxide synthase (NOS), an en-
zyme that produces nitric oxide (NO), 
is another component of the DGC8. It 
has been implicated that dystrophin-de-
ficient muscle is a consequence of neu-
ronal NOS (nNOS) deficiency and not 
nNOS mislocalization12. Because NO is 
a versatile and rapid reactant with other 
free radicals, the extreme disruptions 
of its production in muscle could cause 
major shifts in the redox environment of 
the muscle. Furthermore, NO functions 
as a pluripotent signaling molecule in 
muscles and other tissues and perturba-
tions in its production could have broad 
effects on muscle homeostasis13. Ex-
perimental evidence demonstrates the 
importance of neuronal NOS deficiency 
in the pathology of mdx dystrophy. Ex-
pression of a muscle-specific neuronal 
NOS transgene in dystrophic muscle 
prevented the majority of histologically 
discernible pathology in mdx mice, in-
cluding reducing sarcolemmal lesions 
by about 80%.14
Mitochondria are implicated in oxida-
tive stress and abundant evidence im-
plicates oxidative stress as a potential 
regulator of proteolytic pathways lead-
ing to muscle atrophy during periods of 
prolonged disuse disease15. Mitochon-
drial DNA (mtDNA) is a short circular 
molecule of packed form of DNA. The 
rapid evolution and maternal inheritance 
of mtDNA make it a valuable marker 
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for progeny of a given mother16,17. Since 
inefficient splicing of dystrophin gene 
during its expression can be implicat-
ed as the cause of dystrophin inactive 
protein18, mutation in tRNA can be ex-
pected to be the cause. It has been lately 
identified that mtDNA mutation in the 
tRNA (Met) gene presented by muscle 
weakness, severe exercise intolerance, 
lactic acidosis and growth retardation. 
Muscle biopsy showed unusually se-
vere dystrophic features in muscle bi-
opsies19. Accordingly, it is important to 
raise a sensitive method to detect mtD-
NA mutations.20,21  
The aim of the present study is to find 
new biomarkers implicated in pathogen-
esis of DMD. Those biological markers 
are: Caveolin 3, nitric oxide synthetases 
expression and mitochondrial tRNA 
(Met) gene and caveolin 3 mutations.
PATIENTS AND METHODS                 
Subjects were 24 DMD diagnosed boys 
clinically and at the molecular level, 
mean age 8.1 ± 1.9 years versus 20 age 
and socioeconomic matching healthy 
boys, mean of age 8.2 ± 2.2. Patients 
and controls were chosen to be free 
from any infection and receiving no 
therapeutic treatment known to increase 
the oxidative stress. Blood samples 
were drawn after their parents’ consent.
Reverse Transcriptase - polymerase 
Chain Reaction (RT-PCR) Analysis for 
Caveolin-3 and Nitric Oxide synthase 
Genes.
Total RNA was extracted from cir-
culating mononuclear cells separated 
from the peripheral blood by Ficoll-
Hypaque density gradient separation 
using Histopaque-1077 (Sigma), us-
ing QIAGEN RNeasy extraction Kit 
extraction kit (QIAGEN Inc, USA). 
The RNA samples were reverse tran-
scribed using Superscript reverse tran-
scriptase, using QIAGEN OneStep 
RT-PCR kit (QIAGEN) according to 
manufacturer’s instructions. 10 μl of 
RT reaction were mixed with different 
primers together with 25 μl of Ready 
Mix RedTaq PCR. Primer pairs for ca-








and β-actin samples (forward: 5’-GTG 
GGG CGC CCC AGG CAC CA-3’; 
reverse: 5’-CTC CTT AAT GTC ACG 
CAC GAT TTC-3’). iNOS was ampli-
fied with the following cycle param-
eters: 95°C for 3 minutes; 94°C for 45 
seconds; 59°C for 45 seconds, 72°C for 
2 minutes for 35 cycles, then 72°C, for 
7 minutes and 4°C for 24 hours. PCR 
for caveolin initial denaturation was for 
15 min at 95°C, followed by 40 cycles 
of 30 s at 94°C, 30 s at 55°C and 30 
s at 72°C, with final extension at 72°C 
for 10 min. PCR for β-actin were run 
in the following procedures: at 94°C for 
7 min, 1 circle; at 94°C for 1 min, at 
72°C for 1 min, 30 cycles; at 72°C for 7 
min. Reaction products were then sepa-
rated on a 1.2% agarose gel, ethidium 
stained and photographed. The size of 
the PCR fragments representing iNOS 
was 557 bp, β-actin 540 and caveolin 
345 bp.
Genomic and mtDNA extraction:
Total DNA (including mtDNA) was 
extracted from peripheral blood lym-
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phocytes by Takara DNA extraction 
kit. After DNA extraction, about 50 μg 
DNA at 150-500 ng/μL concentration 
was obtained.
SSCP Analysis:
SSCP analyses were used to screen for 
CAV gene and tRNA(Met) gene mu-
tations. Cav 3 primers were GAGTT-
GAGGCTTCCCTTGCC and reverse 
CGAACAGGAAGCCCCAGAG-
CA. Mitochondrial met was mtD-
NA primer pairs were (sense 
primer 5’-CAAATTCCTCCCTG-
TACGAAAGG-3’; antisense primer 
5’-AATGAGGAGTAGG AGGTTG-
GCC-3’). PCR was carried out. PCR 
amplification was carried out in a Per-
kin-Elmer System thermocycler using 
the following profile: 1 cycle of dena-
turation at 94°C for 5 minutes; 5 cycles 
at 94°C for 20 seconds, 64°C for 20 
seconds, 72°C for 30 seconds and 25 
cycles of 94°C for 20 seconds, 62°C for 
20 seconds, 72°C for 30 seconds; fol-
lowed by a 5-minute extension at 72°C. 
Amplified samples were diluted with 
50 μl of formamide buffer and 50 μl 
of 0.1% SDS/10 mmol/L EDTA. The 
mixture was denatured at 94°C for 5 
minutes, then cooled rapidly on ice and 
held for 5 minutes. For each sample, 3 
to 5 μl was loaded onto 10% nondena-
turing polyacrylamide and run at 8 W 
overnight at room temperature, stained 
and photographed.
RESULTS                                                                  
Results showed significantly increased 
expression in caveolin 3 mRNA relative 
expression (1.5 ± 0.4 vs.1 ± 0.3) among 
DMD patients compared to controls 
(Fig. 1 and Table 1), whose expression 
was measured as a relative expression 
to β-actin mRNA expression (Fig. 2). 
Relative expression of iNOS was sig-
nificantly lower among DMD patients 
compared to controls (1.2 ± 0.6 vs. 
1.9 ± 2.2) as demonstrated in (Table 1 
and Fig. 3).
Applying the SSCP, there was only 
one patient presented a mutation in the 
caveolin gene compared to controls 
(Fig. 4) and no evidence for tRNA 
(Met) gene mutation among DMD pa-
tients (Fig. 5).
Table 1: Relative mRNA expression in iducible nitric oxide synthase and caveolin 3.
DMD Controls t  & p
Caveolin 3 mRNA 1.5 ± 0.4 1 ± 0.3 t= 8.5, p < 0.0000001
Nitric Oxide mRNA 1.2 ± 0.6 1.9 ± 2.2 t = 11.2, p < 0.0001
Fig. 1: Caveolin 3 mRNA relative expression in DMD patients compared to controls. Lanes 13- are 
controls and lanes 46- are DMD patients. It is evident that DMD patients have a higher expression of 
Caveolin-3 mRNA compared to controls.
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Fig. 2: β-actin mRNA expression in DMD patients compared to controls. No significant differences in. 
β-actin mRNA between DMD and Controls.
Fig. 3: iNOS  mRNA expression in DMD patients compared to controls. Lanes 13- are controls and 
lanes 48- are DMD patients. It is evident that DMD patients have a lower expression of iNOS mRNA 
compared to controls.
Fig. 4: SSCP chart for Caveolin 3. Lanes 15- denotes controls and 614- denotes DMD cases. Mutation 
is observed in case 10.
Fig. 5: SSCP chart for tRNA (Met) gene. Lanes 15- denotes controls and 611- denotes DMD cases. No 
mutations are observed neither in cases nor controls.
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DISCUSSION                                                    
iNOS is a nitric oxide (NO) producing 
enzyme. NO has been shown to play 
an important role in the regulation of 
blood flow in exercising skeletal mus-
cle by modulating the vasoconstrictor 
response to activation of -adrenergic 
receptors22,23. In healthy muscles, NO 
has been implicated in myofiber dif-
ferentiation24, modulation of contractile 
force (and exercise-induced glucose 
uptake25. Also, NO has a potential role 
in protecting cells from damage oxygen 
intermediate superoxide, when there is 
an imbalance in the production of ei-
ther NO or superoxide because of the 
altered chemistry for the production of 
highly reactive free radical peroxyni-
trate26. Previous studies performed to 
evaluate alterations and functions of 
nitric oxide synthase (NOS) in DMD 
depend on studies carried out on ani-
mal models of dystrophic (mdx) mice. 
There is a controversy regarding the ex-
pression of iNOS mRNA in DMD mod-
els. While some studies indicated that 
iNOS mRNA is increasingly expressed 
in (mdx) mice compared to controls27. 
Others indicated by immunohistochem-
ical and Western blot analysis, that 
iNOS is expressed and active in the 
smooth muscle cells of normal mouse 
and defective in young adult (2-month-
old) mdx mice28. Another study demon-
strated the presence of protein inhibitor 
of nNOS (PIN) mRNA, which is sig-
nificantly higher in PIN mRNA in dys-
trophic muscles compared with normal 
muscles of mdx mouse29. However the 
negative correlation between caveolin 
mRNA expression and iNOS expres-
sion supports that increased expression 
of caveolin 3 could be the cause for de-
creased expression of iNOS mRNA.30 
Results of the present study showed 
increased expression of caveolin 3 
mRNA expression in lymphocytes of 
DMD patients compared to controls. 
This provides confirmation to previous 
findings that showed up-regulation of 
caveolin-3 expression in humans with 
DMD31. Increased number of caveolae 
in the skeletal muscles of DMD patients 
has been observed by immo-electron 
microscopy techniques, but not in other 
forms of neuronally based muscular 
dystrophies32. In accordance with an in-
creased number of caveolae in DMD pa-
tients, it was recently reported that mdx 
mice (an animal model of DMD, with 
a dystrophin deficiency) have increased 
levels of caveolin-3 expression in their 
skeletal muscles (by ≈2- to 3-fold).33
Results of the present study showed 
only one case with mutation in caveo-
lin 3 gene. This excludes caveolin gene 
mutation from being associated with all 
cases of DMD pathogenesis. A recent 
study showed that overexpressed wild-
type caveolin-3 as a transgene in mice 
revealed: 
i- A dramatic increase in sarcolemmal 
caveolae.
ii- Hypertrophic, necrotic and regener-
ating skeletal muscle fibers with central 
nuclei.
iii- Down-regulation of dystrophin and 
β-dystroglycan protein expression. This 
implicates the possibility that over-
expression of caveolin-3 disrupts the 
normal processing or structure of the 
dystrophin complex, leading to its deg-
radation. Our current results support 
this hypothesis. In addition, these mice 
showed elevated serum creatine kinase 
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levels, consistent with the myo-necrosis 
observed morphologically.34
Mitochondrial DNA (mtDNA), which 
exhibits a maternal inheritance and a 
high rate of evolution, has been widely 
used as a genetic marker when analyz-
ing maternally inherited diseases35. The 
mammalian mitochondrial genome 
(mtDNA) is a 16–17 kb double-strand-
ed circular DNA molecule of character-
istic low-molecular mass, simple struc-
ture, high evolution rate and maternal 
inheritance, as well as absence of tissue 
specificity. On average, each somatic 
cell has 100–500 mitochondria and 
each mitochondrion has 1–15 mtDNA 
molecule (s).35 
Results of the present study did not de-
tected mitochondrial mutation in DMD 
patients. Interpretation of the mtDNA 
sequence data can be extremely dif-
ficult because mtDNA is highly poly-
morphic and it is often difficult and 
time consuming to establish whether a 
mutation is pathogenic or not, particu-
larly if the base change has not been 
reported before Deleterious mutations, 
which segregate with the disease clini-
cally, are usually (but not exclusively) 
heteroplasmic36. Heteroplasmic mu-
tations means that affected individu-
als have a high percentage of mutated 
mtDNA, while unaffected individuals 
have a lower percentage.36
CONCLUSION                                                       
There is an inverse relation between 
iNOS and Caveolin 3. A significant 
decrease in iNOS mRNA expression 
in neutrophils results in significant in-
creased expression in caveolin 3 mRNA 
in lymphocytes of DMD patients com-
pared to controls. This may be due the 
interaction of caveolins with iNOS10. 
However using SSCP, there was no evi-
dence for tRNA (Met) gene mutation 
among DMD patients and only one pa-
tient presented a mutation in the caveo-
lin gene compared to controls, which 
excludes gene mutation for increased 
caveolin overexpression.
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